September 9, 2011 source: originally published in the San Francisco Business Times Gene Security Network’s race to develop safer, more accurate prenatal test is all business for Matt Rabinowitz — and it’s personal. A relative of Rabinowitz, Gene Security Network’s CEO, took a blood test for the likelihood of Down’s syndrome in her unborn baby and […]Read More
September 28, 2011 source: Wall Street Journal All good things, unfortunately, come to an end. The last year or two have been spectacular for entrepreneurs. Investor enthusiasm has been intense, meaning that start-ups had the upper hand and could get financing at extraordinarily generous terms. But I’m afraid that the curtain is about to fall. […]Read More
September 23, 2011 source: Forbes What the Solyndra Bankruptcy Means for Cleantech Investors by Jennifer Kho. Forbes Contributor As executives of defunct solar-panel manufacturer Solyndra keep mum in Washington, Silicon Valley and Wall Street are discussing what the bankruptcy – and the federal investigation – could mean for investors. “It has an impact; it’s such a […]Read More
September 15, 2011 source: Xconomy For a while, I was optimistic that 2011 would be a good year for venture capital-backed IPOs, and it wasn’t just wishful thinking. There were 72 VC-backed IPOs last year—six times as many as in 2009. The year ended with a bang and 2011 got off to a good start. […]Read More
I will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center. Here’s the panel topic summary, hope to see you there. Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get […]Read More
June 22, 2011 source: Genetic Engineering and Biotechnology News On June 10, a day after withdrawing an $86 million IPO filed in November 2010, Ambit Biosciences reported securing $30 million in Series D-2 equity financing. “The terms currently obtainable in the public marketplace are not sufficiently attractive to the registrant to warrant proceeding with the […]Read More
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.